Cerenome, Inc.
CNSY
Norman LaFrance
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Norman LaFrance
Cerenome, Inc. reported in an 8-K filed June 7, 2024 that Norman LaFrance resigned as Chief Medical Officer, effective June 12, 2024. The proxy statement of Cerenome, Inc. reports total compensation of $637,811 for Norman LaFrance in fiscal 2022, including a base salary of $440,000. Disclosed compensation is on record for 2 fiscal years.
“On June 5, 2024, Plus Therapeutics, Inc. (the "Company") received the resignation of Dr. Norman LaFrance, its Chief Medical Officer. Dr. LaFrance's resignation is effective June 12, 2024.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Cerenome, Inc. (CNSY)
Proxy statement
Start not stated–2024-06-12
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Cerenome, Inc. (CNSY) | Chief Medical Officer | $440,000 | $637,811 |
| 2021 | Cerenome, Inc. (CNSY) | Chief Medical Officer | $60,077 | $292,704 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.